Axsome Therapeutics (AXSM) Q3 2024 Earnings
AXSM·Reported November 12, 2024·Before market open
Axsome Therapeutics reported Q3 2024 revenue of $104.8M, beat analyst consensus of $98.4M by $6.4M. Diluted EPS came in at $-1.34, beat the $-1.38 consensus by $0.04.
Revenue
$104.8Mbeat by $6.4M
Consensus: $98.4MDiluted EPS
$-1.34beat by $0.04
Consensus: $-1.38
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Axsome Therapeutics's Q3 2024 earnings report.
Axsome Therapeutics (AXSM) reported Q3 2024 earnings on November 12, 2024 before market open.
Axsome Therapeutics reported revenue of $104.8M and diluted EPS of $-1.34 for Q3 2024.
Revenue beat the consensus estimate of $98.4M by $6.4M. EPS beat the consensus estimate of $-1.38 by $0.04.
You can read the 10-Q periodic report (0000950170-24-124758) directly on SEC EDGAR. The filing index links above go to sec.gov.